2011 - Fellow of the Royal Society of Canada Academy of Science
His primary areas of investigation include Internal medicine, Gastroenterology, Placebo, Surgery and Crohn's disease. His Internal medicine study which covers Immunology that intersects with Microbiology. His Gastroenterology study incorporates themes from Larazotide, Chemotherapy, Certolizumab pegol, Gluten free and Corticosteroid.
The various areas that he examines in his Placebo study include Crohn's Disease Activity Index, Etrolizumab, Gastrointestinal agent and Infliximab. His work deals with themes such as Vedolizumab, Adalimumab and Pharmacokinetics, which intersect with Surgery. His Crohn's disease research is multidisciplinary, relying on both Methotrexate, Anemia, Randomization and Prednisone.
The scientist’s investigation covers issues in Internal medicine, Gastroenterology, Inflammatory bowel disease, Crohn's disease and Ulcerative colitis. His Internal medicine study incorporates themes from Placebo, Endocrinology and Surgery. His Surgery study focuses on Randomized controlled trial in particular.
His Gastroenterology research is multidisciplinary, incorporating elements of Feces, Urine, Adverse effect and Certolizumab pegol. His work in Inflammatory bowel disease covers topics such as Immunology which are related to areas like Microbiology. His Infliximab research incorporates themes from Gastrointestinal agent, Adalimumab, Maintenance therapy and Retrospective cohort study.
His primary areas of study are Internal medicine, Gastroenterology, Ulcerative colitis, Crohn's disease and Inflammatory bowel disease. He has researched Internal medicine in several fields, including Surgery and Oncology. His study ties his expertise on Immunology together with the subject of Gastroenterology.
His work investigates the relationship between Ulcerative colitis and topics such as Randomized controlled trial that intersect with problems in Observational study, Physical therapy and Placebo. His Crohn's disease research incorporates elements of Cross-sectional study, Mediterranean diet and Moderate to severe. His work deals with themes such as Breastfeeding and Intensive care medicine, which intersect with Inflammatory bowel disease.
Richard N. Fedorak mainly investigates Internal medicine, Crohn's disease, Infliximab, Ulcerative colitis and Gastroenterology. The study incorporates disciplines such as Clostridium difficile and Immunology in addition to Internal medicine. His Crohn's disease research includes elements of Inflammatory bowel disease and Abdominal surgery.
His studies deal with areas such as Gastrointestinal agent and Adalimumab as well as Infliximab. The various areas that Richard N. Fedorak examines in his Ulcerative colitis study include Tolerability, Immune system and Intensive care medicine. The concepts of his Gastroenterology study are interwoven with issues in Immunohistochemistry, Intestinal mucosa, Staining, Stain and Biopsy.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Infliximab Maintenance Therapy for Fistulizing Crohn's Disease
Bruce E. Sands;Frank H. Anderson;Charles N. Bernstein;William Y. Chey.
The New England Journal of Medicine (2004)
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
William J. Sandborn;Brian G. Feagan;Paul Rutgeerts;Stephen Hanauer.
The New England Journal of Medicine (2013)
Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial
Stephen B. Hanauer;William J. Sandborn;Paul Rutgeerts;Richard N. Fedorak.
Adalimumab for Maintenance Treatment of Crohn's Disease: Results of the CLASSIC II Trial
William J Sandborn;Stephen B Hanauer;Paul J Rutgeerts;Richard N Fedorak.
Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.
Brian G Feagan;Gordon R Greenberg;Gary Wild;Richard N Fedorak.
The New England Journal of Medicine (2005)
Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice.
Karen L. Madsen;Jason S. Doyle;Laurence D. Jewell;Michele M. Tavernini.
Methotrexate for the Treatment of Crohn's Disease
B G Feagan;J Rochon;R N Fedorak;E J Irvine.
The New England Journal of Medicine (1995)
A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators.
B G Feagan;R N Fedorak;E J Irvine;G Wild.
The New England Journal of Medicine (2000)
VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis
Rodrigo Bibiloni;Richard N Fedorak;Gerald W Tannock;Karen L Madsen.
The American Journal of Gastroenterology (2005)
The epidemiology of inflammatory bowel disease in Canada: a population-based study.
Charles N Bernstein;Andre Wajda;Lawrence W Svenson;Adrian MacKenzie.
The American Journal of Gastroenterology (2006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: